The lack of knowledge and paucity of support in the application process are immediate actionable barriers to wider utilization of compassionate use in pediatric oncology. more→
OUR PUBLICATIONS
Pediatric Cancer Legislative Yearbook 2017
Download a PDF summary of all pediatric cancer-related legislative initiatives, including 2017 accomplishments and future legislative agenda for 2018. more→
Kids v Cancer End of Year Letter 2017
2017 has been a truly remarkable and exciting year for Kids v Cancer. more→
How the RACE for Children Act will get drugs to kids with cancer (The Cancer Letter, by Nancy Goodman)
Taken together, the RACE for Children Act and the Pediatric PRV program change the landscape of pediatric cancer research. more→
Don’t leave them waiting: How to bring new cancer drugs to kids (Morning Consult, by Elena Gerasimov)
The RACE Act is needed because most kids with cancer are treated with medicines from the time when my mom was young. more→
Kids v Cancer End of Year Letter 2016
KVC 2016 End of Year Letter
Kids v Cancer Pediatric Cancer Legislative Yearbook 2016
The Pediatric Cancer Legislative Yearbook 2016 summarizes the achievements of pediatric cancer advocacy organizations and outlines next steps for 2017. more→
Too many PD-1 trials for adults, too few for children (The Cancer Letter, by Nancy Goodman)
Why are there so few trials for which children and young teens would qualify? Shouldn’t kids and teens also get a shot at exciting investigational drugs? more→
Compassionate Use Navigator addresses challenges and facilitates access to investigational drugs for pediatric oncologists (Proceedings: AACR 107th Annual Meeting 2016)
Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA Elena Gerasimov, Lindy Zhang, Scott Moerdler, Michael Roth, Nancy Goodman more→
Saved Josh: The gears of a successful patient advocacy campaign (Case study, by Elena Gerasimov)
Read a detailed account of a case of a 7-year-old boy whose request to be treated with an experimental drug started the nationwide conversation about compassionate use. more→
Kids v Cancer End of Year Letter 2015
Dear Friends of Kids v Cancer, Thank you. It has been a banner year. We have created almost one billion dollars in more→
Laws need to catch up to the science (The Cancer Letter, by Nancy Goodman)
Kids with cancer are the last, not the first, to get on trials of promising new drugs. more→
Kids v Cancer End of Year Letter 2014
Friends of Kids v Cancer: Thank you With your support, we have achieved notable results this year in our efforts to change more→
Kids with cancer need access to drug trials (CNBC)
We have reached a first tipping point in pediatric drug development. Where it was once financially unfeasible, businesses now have a good, bottom-line oriented reason to develop drugs for kids with cancer and the rare diseases. more→